Phase 3 Evaluation of the Islatravir (EFdA) Monthly Oral Formulation
To support the clinical development program of Islatravir for HIV prevention, specifically for the IMPOWER Phase 3 efficacy and safety trial among women and adolescent girls in Sub-Saharan Africa.
Countries
Active Dates
01/01/2021 to 12/01/2025
Faculty Involved